◆ TICKERBASE · GLOBAL STOCK FINANCIAL DATA LIBRARY

Home › All stocks › A › AUPH

Aurinia Pharmaceuticals Inc (AUPH) Financial History

20 years of revenue, earnings, cash-flow and balance-sheet history from public filings.

HEALTHCARE · BIOTECHNOLOGY · DATA UPDATED 2026-09-06

Aurinia Pharmaceuticals Inc (AUPH) operates in the BIOTECHNOLOGY industry and is headquartered in Edmonton, Canada with about 128 employees. Its market capitalization is roughly $2 billion. In the fiscal year ended 2025-12-31, AUPH reported $283M in revenue and $287M in net income.

Aurinia Pharmaceuticals Inc., a biopharmaceutical company, engages in delivering therapies to people living with autoimmune diseases with high unmet medical needs in the United States and Japan. The company offers LUPKYNIS (voclosporin), an oral therapy for the treatment of adult patients with active lupus nephritis.

Interactive charts & full statements → Open the AUPH valuation workbench →

AUPH Revenue & Earnings History — Annual Income Statement

Income statement	TTM → 2026-06-30	2025-12-31	2024-12-31	2023-12-31	2022-12-31	2021-12-31	2020-12-31	2019-12-31	2018-12-31	2017-12-31	2016-12-31	2015-12-31	2014-12-31	2013-12-31	2012-12-31	2011-12-31	2010-12-31	2009-12-31	2008-12-31	2007-12-31	2006-12-31
Total Revenue	$312M	$283M	$235M	$176M	$134M	$46M	$50M	$0M	$0M	$0M	$0M	$0M	$0M	$1M	$6M	$1M	$3M	$4M	$4M	$2M	$4M
Gross Profit	$281M	$250M	$207M	$161M	$128M	$45M	$50M	$0M	($41M)	$0M	$0M	$0M	$0M	$1M	$6M	$1M	$3M	$3M	$2M	$1M	$3M
Gross Margin %	90.4%	88.5%	88.0%	91.9%	95.8%	97.6%	100.0%	100.0%	-8837.8%	99.8%	97.7%	94.9%	86.7%	99.9%	99.2%	80.0%	98.5%	85.8%	45.4%	55.0%	83.0%
Operating Income (EBIT)	$151M	$105M	($5M)	($92M)	($111M)	($181M)	($104M)	($91M)	($56M)	($47M)	($23M)	($24M)	($17M)	($6M)	($5M)	($6M)	($5M)	($10M)	($16M)	($36M)	($24M)
Operating Margin %	48.4%	37.1%	-2.0%	-52.2%	-83.2%	-396.3%	-208.1%	-28598.4%	-12129.2%	-11205.5%	-13187.3%	-10034.0%	-6216.6%	-580.4%	-88.8%	-694.2%	-147.5%	-247.9%	-422.0%	-1543.0%	-685.7%
Net Income	$314M	$287M	$6M	($78M)	($108M)	($181M)	($103M)	($88M)	($64M)	($71M)	($23M)	($19M)	($17M)	($3M)	($10M)	($2M)	($4M)	($8M)	($16M)	($34M)	($23M)
Net Margin %	100.8%	101.5%	2.5%	-44.5%	-80.7%	-396.8%	-204.9%	-27794.0%	-13848.8%	-16855.2%	-13465.3%	-7917.9%	-5988.1%	-268.4%	-158.1%	-259.6%	-107.0%	-187.5%	-409.7%	-1448.7%	-648.7%
EBITDA	$188M	$128M	$32M	($63M)	($109M)	($177M)	($103M)	($90M)	($54M)	($46M)	($21M)	($22M)	($16M)	($6M)	($9M)	($2M)	($4M)	($5M)	($14M)	($34M)	($23M)
Earnings Per Share (EPS)	$2.28	$2.07	$0.04	$-0.54	$-0.76	$-1.40	$-0.87	$-0.95	$-0.76	$-0.92	$-0.66	$-0.58	$-0.57	$-0.40	$-2.74	$-0.70	$-1.44	$-3.17	$-7.47	$-16.34	$-13.56
Shares Outstanding (M)	134M	139M	146M	143M	142M	129M	118M	93M	85M	77M	35M	32M	29M	6M	4M	3M	3M	2M	2M	2M	2M

USD; $M / $B as marked. Newest period first. Source: public company filings (via Yahoo Finance aggregation).

AUPH Quarterly Revenue & Earnings — Last 8 Quarters

Quarterly income statement	2026-06-30	2026-03-31	2025-12-31	2025-09-30	2025-06-30	2025-03-31	2024-12-31	2024-09-30
Total Revenue	$83M	$78M	$77M	$73M	$70M	$62M	$60M	$68M
Gross Profit	$77M	$71M	$69M	$65M	$63M	$54M	$54M	$62M
Gross Margin %	92.1%	91.6%	89.0%	88.4%	89.8%	86.3%	90.7%	91.1%
Operating Income (EBIT)	$46M	$41M	$33M	$30M	$20M	$22M	($2M)	$12M
Operating Margin %	55.7%	53.3%	43.1%	40.5%	28.7%	35.0%	-2.8%	17.3%
Net Income	$37M	$34M	$211M	$32M	$22M	$23M	$1M	$14M
Net Margin %	45.0%	44.2%	273.3%	43.0%	30.7%	37.4%	2.4%	21.2%
EBITDA	$55M	$50M	$47M	$37M	$28M	$30M	$7M	$21M
Earnings Per Share (EPS)	$0.28	$0.25	$1.52	$0.23	$0.15	$0.17	$0.01	$0.10
Shares Outstanding (M)	134M	138M	139M	136M	143M	139M	148M	146M

USD; $M / $B as marked. Newest period first. Source: public company filings (via Yahoo Finance aggregation).

AUPH Free Cash Flow History

Cash flow	TTM → 2026-06-30	2025-12-31	2024-12-31	2023-12-31	2022-12-31	2021-12-31	2020-12-31	2019-12-31	2018-12-31	2017-12-31	2016-12-31	2015-12-31	2014-12-31	2013-12-31	2012-12-31	2011-12-31	2010-12-31	2009-12-31	2008-12-31	2007-12-31	2006-12-31
Cash from Operations (CFO)	$174M	$136M	$44M	($33M)	($80M)	($158M)	($70M)	($64M)	($52M)	($41M)	($19M)	($18M)	($17M)	($5M)	($7M)	($1M)	($4M)	($10M)	($17M)	($28M)	($21M)
Capital Expenditures (CapEx)	$0M	$0M	$0M	$1M	$0M	$2M	$7M	$0M	$0M	$0M	$0M	$0M	$0M	$0M	$0M	$1M	$0M	$0M	$0M	$1M	$1M
Free Cash Flow (FCF)	$174M	$135M	$44M	($34M)	($80M)	($159M)	($77M)	($64M)	($52M)	($41M)	($19M)	($18M)	($17M)	($5M)	($7M)	($3M)	($4M)	($11M)	($18M)	($29M)	($22M)
FCF Margin %	55.7%	47.8%	18.8%	-19.5%	-59.6%	-349.1%	-154.0%	-20027.0%	-11163.1%	-9808.1%	-10831.2%	-7581.3%	-6112.9%	-487.8%	-106.9%	-270.2%	-129.3%	-263.8%	-457.3%	-1256.2%	-631.7%

USD; $M / $B as marked. Newest period first. Source: public company filings (via Yahoo Finance aggregation).

AUPH Quarterly Free Cash Flow — Last 8 Quarters

Quarterly cash flow	2026-06-30	2026-03-31	2025-12-31	2025-09-30	2025-06-30	2025-03-31	2024-12-31	2024-09-30
Cash from Operations (CFO)	$52M	$33M	$45M	$44M	$44M	$1M	$30M	$17M
Capital Expenditures (CapEx)	$0M	$0M	$0M	$0M	$0M	$0M	$0M	$0M
Free Cash Flow (FCF)	$52M	$33M	$45M	$44M	$44M	$1M	$30M	$17M
FCF Margin %	62.7%	41.9%	57.7%	60.4%	63.0%	2.1%	50.2%	25.0%

USD; $M / $B as marked. Newest period first. Source: public company filings (via Yahoo Finance aggregation).

AUPH Balance Sheet History

Balance sheet	2026-06-30	2025-12-31	2024-12-31	2023-12-31	2022-12-31	2021-12-31	2020-12-31	2019-12-31	2018-12-31	2017-12-31	2016-12-31	2015-12-31	2014-12-31	2013-12-31	2012-12-31	2011-12-31	2010-12-31	2009-12-31	2008-12-31	2007-12-31	2006-12-31
Total Assets	$792M	$752M	$551M	$548M	$471M	$543M	$464M	$324M	$146M	$190M	$57M	$34M	$52M	$23M	$4M	$14M	$10M	$10M	$27M	$43M	$31M
Cash & Cash Equivalents	$180M	$80M	$83M	$49M	$94M	$232M	$272M	$306M	$118M	$166M	$40M	$6M	$23M	$2M	$0M	$6M	$6M	$5M	$21M	$32M	$13M
Total Liabilities	$177M	$170M	$173M	$170M	$65M	$64M	$56M	$26M	$33M	$24M	$21M	$14M	$7M	$10M	$6M	$8M	$4M	$5M	$19M	$14M	$10M
Total Debt (Short + Long-Term)	$16M	$18M	$15M	$16M	$1M	$1M	$1M	$7M	$0M	$16M	$12M	$5M	$11M	$1M	$2M	$0M	$0M	$0M	$13M	$1M	$2M
Total Shareholders' Equity	$615M	$581M	$377M	$378M	$405M	$479M	$408M	$299M	$113M	$166M	$36M	$20M	$45M	$13M	($2M)	$6M	$6M	$5M	$8M	$28M	$20M

USD; $M / $B as marked. Newest period first. Source: public company filings (via Yahoo Finance aggregation).

Quarterly statements, profitability ratios, price history, insider activity and institutional holders are in the interactive AUPH viewer.

Other Companies in BIOTECHNOLOGY

VERA · Vera Therapeutics Inc — $2 billion
HRMY · Harmony Biosciences Holdings — $2 billion
SLS · Sellas Life Sciences Group Inc — $2 billion
NKTR · Nektar Therapeutics — $2 billion
GENB · Generate Biomedicines, Inc. Common Stock — $2 billion
OCUL · Ocular Therapeutix Inc — $2 billion
PVLA · Palvella Therapeutics, Inc — $2 billion
TRVI · Trevi Therapeutics Inc — $2 billion

← AUNA All “A” companies AUR →

About TickerBase · Data methodology & sources · Privacy · Terms

TickerBase is provided for educational and informational purposes only. It does not constitute financial, investment, tax, or legal advice, or a recommendation to buy, sell, or hold any security. No price targets are published; any per-share value shown in the valuation workbench is generated entirely from reader-supplied assumptions and is not the publisher's view of fair value. Past performance does not predict future results. Figures are approximate and drawn from public filings; one-time items are noted where identified. Do your own research and consult a licensed professional before making any investment decision. The author may or may not hold positions in the securities discussed.